AbbVie Inc. Cash and Cash Equivalents, Period Increase (Decrease)
AbbVie Inc. (ABBV) reported Cash and Cash Equivalents, Period Increase (Decrease) of $32.63 billion for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-21.
Discontinued › Cash Flow › Change in Cash
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2020-02-21
- AbbVie Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-12-31 was $29.28B.
- AbbVie Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-09-30 was $5.48B, a 22.56% increase year-over-year.
- AbbVie Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-06-30 was $275.00M.
- AbbVie Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2019-03-31 was -$2.39B.
- AbbVie Inc. cash and cash equivalents, period increase (decrease) for fiscal 2019 was $32.63B.
- AbbVie Inc. cash and cash equivalents, period increase (decrease) for fiscal 2018 was -$2.01B, a 147.92% decline from fiscal 2017.
- AbbVie Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was $4.20B.
- AbbVie Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was -$3.30B, a 6568.63% decline from fiscal 2015.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month |
|---|---|---|---|---|
| 2019-12-31 | $29.28B derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $34.75B derived: sum of 2 quarters · filed 2020-02-21 | $35.03B derived: sum of 3 quarters · filed 2020-02-21 | $32.63B 10-K · filed 2020-02-21 |
| 2019-09-30 | $5.48B derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $5.75B derived: sum of 2 quarters · filed 2019-11-06 | $3.36B 10-Q · filed 2019-11-06 | $2.63B derived: sum of 4 quarters · filed 2020-02-21 |
| 2019-06-30 | $275.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$2.12B 10-Q · filed 2019-08-05 | -$2.84B derived: sum of 3 quarters · filed 2020-02-21 | $1.63B derived: sum of 4 quarters · filed 2020-02-21 |
| 2019-03-31 | -$2.39B 10-Q · filed 2019-05-03 | -$3.12B derived: sum of 2 quarters · filed 2020-02-21 | $1.35B derived: sum of 3 quarters · filed 2020-02-21 | -$4.11B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-12-31 | -$726.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $3.74B derived: sum of 2 quarters · filed 2020-02-21 | -$1.72B derived: sum of 3 quarters · filed 2020-02-21 | -$2.01B 10-K · filed 2020-02-21 |
| 2018-09-30 | $4.47B derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$992.00M derived: sum of 2 quarters · filed 2019-11-06 | -$1.29B 10-Q · filed 2019-11-06 | -$431.00M derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-06-30 | -$5.46B derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | -$5.76B 10-Q · filed 2019-08-05 | -$4.90B derived: sum of 3 quarters · filed 2020-02-21 | -$2.54B derived: sum of 4 quarters · filed 2020-02-21 |
| 2018-03-31 | -$296.00M 10-Q · filed 2019-05-03 | $561.00M derived: sum of 2 quarters · filed 2020-02-21 | $2.92B derived: sum of 3 quarters · filed 2020-02-21 | $4.27B derived: sum of 4 quarters · filed 2020-02-21 |
| 2017-12-31 | $857.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $3.21B derived: sum of 2 quarters · filed 2020-02-21 | $4.56B derived: sum of 3 quarters · filed 2020-02-21 | $4.20B 10-K · filed 2020-02-21 |
| 2017-09-30 | $2.36B derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $3.71B derived: sum of 2 quarters · filed 2018-11-07 | $3.35B 10-Q · filed 2018-11-07 | $2.23B derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $1.35B derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $988.00M 10-Q · filed 2018-08-07 | -$130.00M derived: sum of 3 quarters · filed 2019-02-27 | -$239.00M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | -$360.00M 10-Q · filed 2018-05-04 | -$1.48B derived: sum of 2 quarters · filed 2019-02-27 | -$1.59B derived: sum of 3 quarters · filed 2019-02-27 | -$2.82B derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | -$1.12B derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$1.23B derived: sum of 2 quarters · filed 2019-02-27 | -$2.46B derived: sum of 3 quarters · filed 2019-02-27 | -$3.30B 10-K · filed 2019-02-27 |
| 2016-09-30 | -$109.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$1.34B derived: sum of 2 quarters · filed 2017-11-07 | -$2.18B 10-Q · filed 2017-11-07 | -$3.00B derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-06-30 | -$1.23B derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | -$2.07B 10-Q · filed 2017-08-07 | -$2.90B derived: sum of 3 quarters · filed 2018-02-16 | -$1.07B derived: sum of 4 quarters · filed 2018-02-16 |
| 2016-03-31 | -$843.00M 10-Q · filed 2017-05-05 | -$1.67B derived: sum of 2 quarters · filed 2018-02-16 | $156.00M derived: sum of 3 quarters · filed 2018-02-16 | -$350.00M derived: sum of 4 quarters · filed 2018-02-16 |
| 2015-12-31 | -$824.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $999.00M derived: sum of 2 quarters · filed 2018-02-16 | $493.00M derived: sum of 3 quarters · filed 2018-02-16 | $51.00M 10-K · filed 2018-02-16 |
| 2015-09-30 | $1.82B derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $1.32B derived: sum of 2 quarters · filed 2016-11-07 | $875.00M 10-Q · filed 2016-11-07 | $1.50B derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-06-30 | -$506.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | -$948.00M 10-Q · filed 2016-08-05 | -$319.00M derived: sum of 3 quarters · filed 2017-02-17 | -$1.69B derived: sum of 4 quarters · filed 2017-02-17 |
| 2015-03-31 | -$442.00M 10-Q · filed 2016-05-06 | $187.00M derived: sum of 2 quarters · filed 2017-02-17 | -$1.18B derived: sum of 3 quarters · filed 2017-02-17 | |
| 2014-12-31 | $629.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | -$738.00M derived: sum of 2 quarters · filed 2017-02-17 | -$1.25B 10-K · filed 2017-02-17 | |
| 2014-09-30 | -$1.37B derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | -$1.88B 10-Q · filed 2015-11-06 | ||
| 2014-06-30 | -$509.00M 10-Q · filed 2015-08-07 | |||
| 2013-12-31 | $3.69B 10-K · filed 2016-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |